LUminate Support app for iPhone and iPad

LUminate is the official support app designed to assist patients taking LUCEMYRA (lofexidine) tablets as they go through opioid withdrawal. With customizable dose tracking, timely medication reminders, and daily mes- sages of encouragement, the LUminate app is designed to support patients while they go through withdrawal during each day of treatment with LUCEMYRA. Signup is not required — simply download the app and start immediately!

FEATURES INCLUDE:
- Dose Tracking/Reminders
- Supportive messages each day of treatment
- Symptom Library (including advice and tips for relief)
- Meditation Timer


INDICATION
LUCEMYRA is indicated for mitigation of opioid with- drawal symptoms to facilitate abrupt opioid discontinu- ation in adults.

IMPORTANT SAFETY INFORMATION
LUCEMYRA will not stop you from craving opioids. LUCEMYRA is not an opioid and will not produce the effects seen when taking opioids.
LUCEMYRA may lessen the severity of your symptoms, but it may not completely prevent them.

After a period of not using opioids, you may be more sensitive to the effects of lower amounts of opioids. Taking opioids in amounts that you used before stop- ping opioid use, whether with or without LUCEMYRA, can lead to overdose and death. It is important that you, your family, and the people closest to you are aware of this increased risk of overdose.

Alcohol, barbiturates, and benzodiazepines should be used with caution while taking LUCEMYRA as serious side effects may occur.

Tell your healthcare provider if you have ever been diag- nosed with kidney disease or liver disease.

LUCEMYRA may cause low blood pressure or slower heart rate. Tell your healthcare provider if you have ever been diagnosed with low blood pressure, slow heart rate, any other cardiac abnormality (including prior di- agnosis or family history of long QT syndrome), or if you have had a heart attack.

Tell your healthcare provider about all medications you are taking. LUCEMYRA should be used with caution with any medications that decrease pulse or blood pressure.

Watch for signs of a drop in your blood pressure or heart rate, including dizziness, lightheadedness, or feelings of faintness either when sitting or if you quickly stand up. If you experience these symptoms, call your healthcare provider and do not take your next dose of LUCEMYRA until you have talked to your healthcare provider.

It is important to stay hydrated while taking LUCEMYRA during opioid discontinuation or withdrawal.

The most common side effects seen with LUCEMYRA are low blood pressure or symptoms such as lighthead- edness, slow heart rate, dizziness, sleepiness, and dry mouth.

Talk to your healthcare provider before taking other medications for individual symptoms of withdrawal (such as pain relievers, sleep aids, or medications for upset stomach). Your healthcare provider will tell you whether it is safe to take LUCEMYRA with other medi- cations you may be prescribed during opioid discontin- uation (such as buprenorphine/naloxone, methadone, naltrexone).

LUCEMYRA should not be stopped abruptly. Consult your healthcare provider before stopping or reducing your LUCEMYRA dose.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact US WorldMeds at 1-833-LUCEMYRA or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

The LUminate Support App is for your personal use only. By using the LUminate Support App, you under- stand and acknowledge the information that you put into the LUminate Support App will not be accessed by anyone other than you.

Please note that all comments posted on iTunes are not associated with, endorsed by, or monitored by US WorldMeds, LLC.

US WorldMeds will not respond to comments posted on iTunes. Instead, please contact us directly at 1-833- LUCEMYRA. If you are experiencing a medical emergency, call 911 immediately.